Law360, Washington (February 14, 2012, 6:59 PM EST) -- Seattle-based biotechnology company Cell Therapeutics Inc. agreed to pay $19 million to settle a class action by investors who contended the company's stock price was artificially inflated due to misleading statements about a pipeline drug, according to a Tuesday court filing.
The lead plaintiffs requested conditional class certification for settlement purposes as well as preliminary approval of the settlement in an unopposed motion in Washington federal court.
If approved, the settlement will mark an end of a consolidated class action that accused CTI of misleading investors...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.